Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer
But Competition Will Be Fierce
GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.
